Herdeg Christian, Geisler Tobias, Goehring-Frischholz Katrin, Zuern Christine, Hartmann Ulrike, Haase Karl K, Gawaz Meinrad
Medizinische Klinik III, Eberhard Karls Universitaet Tuebingen, Tuebingen, Germany.
Can J Cardiol. 2008 Apr;24(4):309-11. doi: 10.1016/s0828-282x(08)70182-x.
There is currently no promising interventional solution for in-stent stenosis in previously stented bifurcation lesions, even with drug-eluting stents. Rather than being restricted to stent struts, catheter-based local antiproliferative therapy offers the advantage of homogenous drug transfer to the whole vessel wall, and thereby allows for intracoronary pharmacotherapy without adding additional layers of metal into an already stented lesion. The newly developed GENIE catheter (Acrostak Corp, Switzerland), applied in the kissing balloon technique, allows for delivery of liquid paclitaxel into whole bifurcation lesions without repeat stent implantation. After conventional percutaneous transluminal coronary angioplasty, local delivery of paclitaxel using two GENIE catheters in the kissing balloon technique was performed in three patients (left anterior descending, left circumflex and right coronary arteries) with highly symptomatic in-stent bifurcation stenoses. The intervention was feasible and safe in all coronary arteries. Final angiography and control angiography after six months showed good results. No major adverse cardiac events occurred 30 days and six months after intervention. The patients, who represent a group at high risk of recurrent instent restenosis, remained asymptomatic since the local drug delivery. They did not require insertion of a drug-eluting stent or crossover to coronary artery bypass surgery. In conclusion, this new treatment strategy proved to be safe and effective in this first human experience and offers a promising alternative to surgery or implantation of additional stents in these patients.
对于既往已植入支架的分叉病变中的支架内狭窄,目前尚无有前景的介入治疗方案,即便使用药物洗脱支架也是如此。基于导管的局部抗增殖治疗并非局限于支架小梁,而是具有将药物均匀输送至整个血管壁的优势,从而能够在不向已植入支架的病变部位添加额外金属层的情况下进行冠状动脉内药物治疗。新开发的GENIE导管(瑞士Acrostak公司)应用于球囊对吻技术,可在不重复植入支架的情况下将液态紫杉醇输送至整个分叉病变部位。在3例有高度症状性支架内分叉狭窄的患者(左前降支、左旋支和右冠状动脉)中,在常规经皮冠状动脉腔内血管成形术后,采用球囊对吻技术使用两根GENIE导管进行紫杉醇局部输送。该介入操作在所有冠状动脉中均可行且安全。最终血管造影及6个月后的对照血管造影显示效果良好。干预后30天和6个月均未发生重大不良心脏事件。这些患者属于支架内再狭窄复发高危人群,自局部药物输送后一直无症状。他们无需植入药物洗脱支架或改行冠状动脉旁路移植术。总之,在这首例人体试验中,这种新的治疗策略被证明是安全有效的,为这些患者的手术或植入额外支架提供了一种有前景的替代方案。